CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 52.2%, EPS grew 1,443.8% and free cash flow grew 223.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow CDNA
CareDx, Inc. (CDNA) EV/Sales
As of 16 October 2026, CareDx, Inc. (CDNA) trades at a EV/Sales of 6.4×. Over the past ten years it has ranged from 0.0× (October 2023) to 22.0× (January 2021); the current reading is higher than 69% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (16.40%) |
| FY2024 | 2.6× | 79.00% |
| FY2023 | 1.5× | 55.87% |
| FY2022 | 0.9× | (86.33%) |
| FY2021 | 6.8× | (58.34%) |
| FY2020 | 16.4× | 139.68% |
| FY2019 | 6.9× | (37.86%) |
| FY2018 | 11.0× | 193.63% |
| FY2017 | 3.8× | 242.24% |
| FY2016 | 1.1× | (49.96%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | 40.41% |
| Mar 2026 | 1.7× | (21.97%) |
| Dec 2025 | 2.2× | 36.71% |
| Sep 2025 | 1.6× | (37.96%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. compare | 2.6× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| SHC Sotera Health Company compare | 5.7× |
| CDNA CareDx, Inc. | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)